Pharmaceuticals Search Engine [selected websites]

Loading

Thursday, December 27, 2007

ExonHit Therapeutics, Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease

20 December 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, announced today that it has obtained a regulatory approval to initiate a Phase 2 clinical trial of its therapeutic compound, EHT 0202, in patients with Alzheimer's disease . EHT 0202 is a compound, with a novel mechanism of action, which has shown benefits on memory and neuronal loss... ExonHit's Press Release -

Tuesday, December 18, 2007

EDAP's Ablatherm HIFU treatments, Phase II/III U.S. Clinical Study program seeking FDA approval

LYON, France, Dec. 5, 2007 (PRIME NEWSWIRE) -- EDAP TMS S.A. (Nasdaq:EDAP), the global leader in High Intensity Focused Ultrasound treatment of prostate cancer announced the launch of Ablatherm HIFU treatments at Vanderbilt University Medical Center, Nashville, TN. The treatments are part of EDAP's ongoing Phase II/III U.S. Clinical Study program seeking FDA approval as the first HIFU device for prostate cancer in the United States... EDAP's Press Release -

Monday, December 17, 2007

Stallergenes and Protein Expert, Partnership for producing mites recombinant allergens

December 12, 2007 - STALLERGENES S.A and Protein’eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens .
The partnership is part of the STALLERGENES “Enhanced Allergens” innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system... Stallergenes' Press Release - Version Française

Monday, December 3, 2007

EXONHIT , A PROTOTYPE TO DETECT ALZHEIMER'S DISEASE FROM BLOOD

Paris, France - November 8, 2007 - ExonHit Therapeutics, a drug and diagnostic discovery company, has completed a prototype of the first blood-based Alzheimer's disease test. The company expects to have this test certified and to provide it as a service in its GLP (Good Laboratory Practices) compliant laboratories to the pharmaceutical industry as early as 2009... ExonHit's Press Release - Communiqué de Presse ExonHit -